



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 April 2025
EMA/CHMP/123587/2025
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Jivi

damoctocog alfa pegol

On 25 April 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Jivi. The marketing authorisation holder for this medicinal product is Bayer AG.

The CHMP adopted an extension to the existing indication to include treatment of children from 7 years of age, as follows:²

Treatment and prophylaxis of bleeding in previously treated patients $\geq$ ~~12~~**7** years of age with haemophilia A (congenital factor VIII deficiency).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in bold, removed text as strikethrough

